LGND

#1394
Ligand Pharmaceuticals Inc.
231.2650 USD
+8.35%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
225.8000
231.4350
Jahresspanne
175.8900
231.4350
Tagesänderung
+8.35%
Monatliche Änderung
+13.20%
6 month change
+23.59%
Jahresänderung
+23.59%
Vorheriger Schlusskurs
213.4400
Eröffnung
230.0000
Bid
Ask
Tief
225.8000
High
231.4350
Volumen
91
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden
Vierteljährlich Jährlich
  • Market Capitalization 4.6117 B
  • Employee 47
  • Founded N/A
  • CEO N/A
  • Website www.ligand.com
  • Headquarter Delaware, United States
  • FIGI BBG000BKF014
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
30.84
Preis-Umsatz-Verhältnis
14.31
Dividende je Aktie
2.5
Dividendenrendite in %
1.32

Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol. The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments. Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020.

Nachrichten